HRP20192212T4 - Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova - Google Patents
Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova Download PDFInfo
- Publication number
- HRP20192212T4 HRP20192212T4 HRP20192212TT HRP20192212T HRP20192212T4 HR P20192212 T4 HRP20192212 T4 HR P20192212T4 HR P20192212T T HRP20192212T T HR P20192212TT HR P20192212 T HRP20192212 T HR P20192212T HR P20192212 T4 HRP20192212 T4 HR P20192212T4
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- cell
- expression vector
- nucleic acid
- tcr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 22
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 239000013604 expression vector Substances 0.000 claims 10
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000012931 lyophilized formulation Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 and optionally Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Claims (14)
1. Peptid koji sadrži aminokiselinsku sekvencu u skladu SEQ ID NO. 53, i njezinu farmaceutski prihvatljivu sol, naznačen time što navedeni peptid ima sposobnost vezivanja s molekulom glavnog ljudskog histokompatibilnog kompleksa (MHC) razred-I, i pri čemu je navedeni peptid, kada je vezan na MHC, sposoban da ga prepoznaju CD8 T stanice.
2. Peptid prema patentnom zahtjevu 1, naznačen time što navedeni peptid uključuje nepeptidne veze, i/ili pri čemu je navedeni peptid dio fuzijskog proteina koji sadrži N- terminalne aminokiseline iz HLA-DR invarijantnog lanca povezanog s antigenom (li).
3. Protutijelo, topljivo ili koje se veže za membranu, koje specifično prepoznaje peptid prema patentnom zahtjevu 1, poželjno peptid prema patentnom zahtjevu 1 ili 2 koji se veže za molekulu MHC.
4. T-stanični receptor (TCR), topljiv ili koji se veže za membranu, koji je reaktivan s HLA ligandom, koji se sastoji od aminokiselinske sekvence prema SEQ ID NO. 53.
5. Nukleinska kiselina, koja kodira peptid prema zahtjevu 1 do 2, protutijelo prema zahtjevu 3, TCR prema zahtjevu 4, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
6. Stanica domaćina koja sadrži peptid prema patentnom zahtjevu 1 do 2, ili nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, naznačeni time što je navedena stanica domaćin poželjno stanica koja predstavlja antigen kao što je dendritična stanica, ili T stanica ili NK stanica.
7. Postupak za proizvodnju peptida prema patentnom zahtjevu 1 do 2, ili TCR prema zahtjevu 4, postupak koji se sastoji od kultiviranja stanice domaćina prema zahtjevu 6 koji predstavlja peptid prema patentnom zahtjevu 1 do 2, ili eksprimira nukleinsku kiselinu ili ekspresijski vektor prema zahtjevu 5, i izoliranje navedenog peptida, ili navedenog TCR iz stanice domaćina i/ili njezinog medija za kultiviranje.
8. In vitro postupak za proizvodnju aktiviranih T-limfocita, te postupak obuhvaća dovođenje u kontakt in vitro T stanica s antigenom napunjenim ljudskim MHC molekulama razred I koje se eksprimiraju na površini odgovarajuće stanice koja predstavlja antigen ili umjetni konstrukt koji oponaša stanicu koja predstavlja antigen tijekom vremenskog perioda dovoljnog da se aktiviraju navedene T stanice na antigen specifičan način, pri čemu je navedeni antigen peptid prema zahtjevu 1 ili 2.
9. Aktivirana T stanica, proizvedena postupkom prema patentnom zahtjevu 9, koja selektivno prepoznaje stanicu koja predstavlja polipeptid koji sadrži aminokiselinsku sekvencu navedenu u zahtjevu 1.
10. Farmaceutski pripravak koji sadrži najmanje jedan aktivni sastojak odabran iz skupine koja sadrži peptid prema bilo kojem od patentnih zahtjeva 1 do 2, protutijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinsku kiselinu ili ekspresijski vektor prema zahtjevu 5, stanicu domaćina koja sadrži ekspresijski vektor prema zahtjevu 6, aktiviranu T stanicu prema zahtjevu 9, i farmaceutski prihvatljiv nosač, i po izboru, farmaceutski prihvatljive pomoćne tvari i/ili stabilizatore.
11. Peptid prema bilo kojem od patentnih zahtjeva 1 do 2, protutijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, stanica domaćina koja sadrži ekspresijski vektor prema zahtjevu 6, aktivirana T stanica prema zahtjevu 9, ili farmaceutski pripravak prema zahtjevu 10 za upotrebu u medicini.
12. Peptid prema bilo kojem od patentnih zahtjeva 1 do 2, protutijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, stanica domaćina koja sadrži ekspresijski vektor prema zahtjevu 6, aktivirana T stanica prema zahtjevu 9, ili farmaceutski pripravak prema zahtjevu 10 za upotrebu u liječenju raka.
13. Peptid prema bilo kojem od patentnih zahtjeva 1 do 2, protutijelo prema zahtjevu 3, TCR prema zahtjevu 4, nukleinska kiselina ili ekspresijski vektor prema zahtjevu 5, stanica domaćina koja sadrži ekspresijski vektor prema zahtjevu 6, aktivirana T stanica prema zahtjevu 9, ili farmaceutski pripravak prema zahtjevu 10 za upotrebu prema zahtjevu 12, pri čemu je navedeni rak odabran iz skupine koja sadrži HCC, rak mozga, rak bubrega, rak gušterače, rak debelog crijeva ili rak rektuma, ili leukemiju i druge tumore koji pokazuju prekomjernu ekspresiju CFHR5.
14. Komplet koji sadrži:
(a) spremnik koji sadrži farmaceutski pripravak u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku;
(b) po izboru, drugi spremnik koji sadrži otapalo ili otopinu za rekonstituciju za liofiliziranu formulaciju;
(c) po izboru, najmanje još jedan peptid odabran iz skupine koja sadrži SEQ ID NO. 1 do SEQ ID NO. 52, i SEQ ID NO. 54 do SEQ ID NO. 346, i
(d) po izboru, upute za (i) upotrebu otopine ili (ii) rekonstituciju i/ili upotrebu liofilizirane formulacije i, po izboru,
koji nadalje sadrži jedan ili više od (iii) pufer, (iv) otapalo, (v) filter, (vi) iglu, ili (vii) štrcaljku.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096165P | 2014-12-23 | 2014-12-23 | |
GB201423016 | 2014-12-23 | ||
GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
PCT/EP2015/080018 WO2016102272A1 (en) | 2014-12-23 | 2015-12-16 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
EP15813809.9A EP3236985B2 (en) | 2014-12-23 | 2015-12-16 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20192212T1 HRP20192212T1 (hr) | 2020-03-20 |
HRP20192212T4 true HRP20192212T4 (hr) | 2022-11-25 |
Family
ID=66846825
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211580TT HRP20211580T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20211754TT HRP20211754T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20192212TT HRP20192212T4 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20211753TT HRP20211753T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20211327TT HRP20211327T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211580TT HRP20211580T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20211754TT HRP20211754T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211753TT HRP20211753T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
HRP20211327TT HRP20211327T1 (hr) | 2014-12-23 | 2015-12-16 | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
Country Status (28)
Country | Link |
---|---|
US (10) | US20220016227A1 (hr) |
JP (8) | JP2020191866A (hr) |
KR (4) | KR102643923B1 (hr) |
AU (1) | AU2022268329A1 (hr) |
CL (1) | CL2021001479A1 (hr) |
CO (1) | CO2017003772A2 (hr) |
CR (1) | CR20210289A (hr) |
CY (5) | CY1122491T1 (hr) |
DK (1) | DK3236985T4 (hr) |
ES (5) | ES2887107T3 (hr) |
FI (1) | FI3236985T4 (hr) |
HR (5) | HRP20211580T1 (hr) |
HU (5) | HUE056607T2 (hr) |
IL (1) | IL281752A (hr) |
LT (5) | LT3616706T (hr) |
MA (6) | MA48487B1 (hr) |
MD (5) | MD3626731T2 (hr) |
MX (6) | MX2020004757A (hr) |
MY (1) | MY178137A (hr) |
PE (1) | PE20211740A1 (hr) |
PL (4) | PL3616706T3 (hr) |
PT (5) | PT3626729T (hr) |
RS (1) | RS62575B1 (hr) |
SG (2) | SG10202102698VA (hr) |
SI (2) | SI3626731T1 (hr) |
TW (3) | TW202321273A (hr) |
UA (1) | UA124331C2 (hr) |
ZA (1) | ZA201701762B (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3616706T3 (pl) * | 2014-12-23 | 2022-02-07 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka |
CN114720691B (zh) * | 2022-05-10 | 2022-12-09 | 深圳粒影生物科技有限公司 | 一种检测生物标志物的试剂盒及其制备方法和应用 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
AU2061201A (en) | 1999-12-17 | 2001-06-25 | Chiron Corporation | Mammalian dishevelled-associated proteins |
AU2001232204A1 (en) | 2000-02-22 | 2001-09-03 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20050053918A1 (en) * | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US20070134261A1 (en) * | 2001-12-03 | 2007-06-14 | Hancock Robert E | Effectors of innate immunity |
US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
US20040091503A1 (en) * | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
DE602004015064D1 (de) | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
US20090304679A1 (en) * | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
DK1806359T3 (da) | 2005-09-05 | 2010-06-14 | Immatics Biotechnologies Gmbh | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
DE602005016112D1 (de) | 2005-09-05 | 2009-10-01 | Immatics Biotechnologies Gmbh | Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe |
WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
WO2008156655A2 (en) * | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
WO2009026547A1 (en) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Methods of assaying vaccine potency |
ES2573458T3 (es) | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
EP2262834A4 (en) | 2008-02-27 | 2011-08-17 | Receptor Logic Inc | ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME |
WO2009151487A1 (en) | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Methods of assaying vaccine potency |
DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
WO2010059742A1 (en) * | 2008-11-18 | 2010-05-27 | Collabrx, Inc. | Individualized cancer treatment |
CA2780753A1 (en) | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
CN103501806A (zh) | 2010-11-12 | 2014-01-08 | 赛达斯西奈医疗中心 | 用于治疗和/或预防动脉瘤的免疫调节方法和系统 |
CA2817543A1 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
US20130302362A1 (en) * | 2010-11-12 | 2013-11-14 | Cedars-Sinai Medical Center | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 |
JP6415977B2 (ja) * | 2011-04-15 | 2018-10-31 | ジェネラックス・コーポレイションGenelux Corporation | 弱毒化ワクシニアウイルスのクローン株およびその使用方法 |
US9221876B2 (en) * | 2011-11-11 | 2015-12-29 | Cardiovax, Llc | Methods for treating kidney disease with fragments of ApoB-100 |
GB201208293D0 (en) | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
WO2014039675A2 (en) | 2012-09-05 | 2014-03-13 | University Of Virginia Patent Foundation | Target peptides for colorectal cancer therapy and diagnostics |
GB201301632D0 (en) | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
US9134326B2 (en) | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
CN103739667B (zh) | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
SG11201607181WA (en) | 2014-03-14 | 2016-09-29 | Immunocore Ltd | Tcr libraries |
PL3616706T3 (pl) * | 2014-12-23 | 2022-02-07 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
CA3020555A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
RU2018138838A (ru) | 2016-04-08 | 2020-05-14 | Адаптимьюн Лимитед | Т-клеточные рецепторы |
CA3020530A1 (en) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | T cell receptors |
WO2018022573A1 (en) | 2016-07-27 | 2018-02-01 | Sharp Laboratories Of America, Inc. | Wireless telecommuncations methods and apparatus using system information value tag |
US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
CN110809580A (zh) | 2017-01-24 | 2020-02-18 | 安贝科思生物制剂公司 | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 |
CN110709516B (zh) | 2017-06-05 | 2023-06-27 | 国立大学法人三重大学 | 识别来自mage-a4的肽的抗原结合性蛋白 |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
JP2021500852A (ja) | 2017-08-18 | 2021-01-14 | グリットストーン オンコロジー インコーポレイテッド | 共有抗原を標的にする抗原結合タンパク質 |
US20190201443A1 (en) | 2017-09-06 | 2019-07-04 | California Institute Of Technology | Signaling and antigen-presenting bifunctional receptors (sabr) |
EP3731876A4 (en) | 2017-12-28 | 2022-04-06 | Gritstone bio, Inc. | ANTIGEN-BINDING PROTEINS DIRECTED AGAINST COMMON ANTIGENS |
JP7469807B2 (ja) | 2018-04-19 | 2024-04-17 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Mage-b2特異性を有するt細胞受容体およびその使用 |
EP3796927A4 (en) | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | SHARED ANTIGENS |
US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-12-16 PL PL19199098T patent/PL3616706T3/pl unknown
- 2015-12-16 KR KR1020227028464A patent/KR102643923B1/ko active IP Right Grant
- 2015-12-16 LT LTEP19199098.5T patent/LT3616706T/lt unknown
- 2015-12-16 PE PE2021000187A patent/PE20211740A1/es unknown
- 2015-12-16 ES ES19170191T patent/ES2887107T3/es active Active
- 2015-12-16 PT PT191991017T patent/PT3626729T/pt unknown
- 2015-12-16 MD MDE20200300T patent/MD3626731T2/ro unknown
- 2015-12-16 KR KR1020207030041A patent/KR102435015B1/ko active IP Right Grant
- 2015-12-16 PL PL19199125T patent/PL3626731T3/pl unknown
- 2015-12-16 MY MYPI2017700826A patent/MY178137A/en unknown
- 2015-12-16 LT LTEP15813809.9T patent/LT3236985T/lt unknown
- 2015-12-16 MD MDE20200241T patent/MD3616706T2/ro unknown
- 2015-12-16 PT PT191701911T patent/PT3545965T/pt unknown
- 2015-12-16 MD MDE20170224T patent/MD3236985T3/ro unknown
- 2015-12-16 LT LTEP19199101.7T patent/LT3626729T/lt unknown
- 2015-12-16 RS RS20211420A patent/RS62575B1/sr unknown
- 2015-12-16 ES ES19199098T patent/ES2900106T3/es active Active
- 2015-12-16 HR HRP20211580TT patent/HRP20211580T1/hr unknown
- 2015-12-16 MD MDE20191122T patent/MD3545965T2/ro unknown
- 2015-12-16 SI SI201531746T patent/SI3626731T1/sl unknown
- 2015-12-16 MA MA48487A patent/MA48487B1/fr unknown
- 2015-12-16 MD MDE20200298T patent/MD3626729T2/ro unknown
- 2015-12-16 HR HRP20211754TT patent/HRP20211754T1/hr unknown
- 2015-12-16 MA MA46913A patent/MA46913B1/fr unknown
- 2015-12-16 HU HUE19199125A patent/HUE056607T2/hu unknown
- 2015-12-16 ES ES15813809T patent/ES2763911T5/es active Active
- 2015-12-16 ES ES19199125T patent/ES2899425T3/es active Active
- 2015-12-16 MA MA050819A patent/MA50819A/fr unknown
- 2015-12-16 MA MA049156A patent/MA49156A/fr unknown
- 2015-12-16 HU HUE19170191A patent/HUE055489T2/hu unknown
- 2015-12-16 CR CR20210289A patent/CR20210289A/es unknown
- 2015-12-16 HR HRP20192212TT patent/HRP20192212T4/hr unknown
- 2015-12-16 DK DK15813809.9T patent/DK3236985T4/da active
- 2015-12-16 LT LTEP19170191.1T patent/LT3545965T/lt unknown
- 2015-12-16 MA MA049157A patent/MA49157A/fr unknown
- 2015-12-16 UA UAA201702214A patent/UA124331C2/uk unknown
- 2015-12-16 MA MA49155A patent/MA49155B1/fr unknown
- 2015-12-16 KR KR1020207015687A patent/KR102395995B1/ko active IP Right Grant
- 2015-12-16 HU HUE15813809A patent/HUE046641T2/hu unknown
- 2015-12-16 LT LTEP19199125.6T patent/LT3626731T/lt unknown
- 2015-12-16 SI SI201531736T patent/SI3616706T1/sl unknown
- 2015-12-16 PL PL19199101T patent/PL3626729T3/pl unknown
- 2015-12-16 PT PT191991256T patent/PT3626731T/pt unknown
- 2015-12-16 FI FIEP15813809.9T patent/FI3236985T4/fi active
- 2015-12-16 PL PL19170191T patent/PL3545965T3/pl unknown
- 2015-12-16 HU HUE19199098A patent/HUE057014T2/hu unknown
- 2015-12-16 PT PT158138099T patent/PT3236985T/pt unknown
- 2015-12-16 SG SG10202102698VA patent/SG10202102698VA/en unknown
- 2015-12-16 HR HRP20211753TT patent/HRP20211753T1/hr unknown
- 2015-12-16 HU HUE19199101A patent/HUE056087T2/hu unknown
- 2015-12-16 ES ES19199101T patent/ES2896919T3/es active Active
- 2015-12-16 PT PT191990985T patent/PT3616706T/pt unknown
- 2015-12-16 KR KR1020247006647A patent/KR20240033128A/ko not_active Application Discontinuation
- 2015-12-16 HR HRP20211327TT patent/HRP20211327T1/hr unknown
- 2015-12-16 SG SG10202101444UA patent/SG10202101444UA/en unknown
- 2015-12-21 TW TW112102743A patent/TW202321273A/zh unknown
- 2015-12-21 TW TW109139864A patent/TWI794679B/zh active
- 2015-12-21 TW TW109103806A patent/TWI754892B/zh active
-
2017
- 2017-03-10 ZA ZA2017/01762A patent/ZA201701762B/en unknown
- 2017-04-19 CO CONC2017/0003772A patent/CO2017003772A2/es unknown
- 2017-06-21 MX MX2020004757A patent/MX2020004757A/es unknown
- 2017-06-21 MX MX2020011791A patent/MX2020011791A/es unknown
- 2017-06-21 MX MX2020011794A patent/MX2020011794A/es unknown
- 2017-06-21 MX MX2020005188A patent/MX2020005188A/es unknown
- 2017-06-21 MX MX2020011793A patent/MX2020011793A/es unknown
- 2017-06-21 MX MX2020011787A patent/MX2020011787A/es unknown
-
2019
- 2019-12-17 CY CY20191101328T patent/CY1122491T1/el unknown
-
2020
- 2020-06-12 JP JP2020102006A patent/JP2020191866A/ja active Pending
- 2020-06-12 JP JP2020102005A patent/JP7358299B2/ja active Active
- 2020-06-12 JP JP2020102004A patent/JP7109801B2/ja active Active
- 2020-06-15 JP JP2020102993A patent/JP7448423B2/ja active Active
- 2020-06-15 JP JP2020102991A patent/JP2020191867A/ja not_active Ceased
- 2020-06-15 JP JP2020102992A patent/JP7346361B2/ja active Active
- 2020-06-19 JP JP2020106475A patent/JP7026411B2/ja active Active
-
2021
- 2021-03-23 IL IL281752A patent/IL281752A/en unknown
- 2021-06-04 CL CL2021001479A patent/CL2021001479A1/es unknown
- 2021-10-01 US US17/492,112 patent/US20220016227A1/en active Pending
- 2021-10-06 CY CY20211100869T patent/CY1124533T1/el unknown
- 2021-10-15 US US17/502,170 patent/US20220023403A1/en active Pending
- 2021-10-15 US US17/502,185 patent/US20220023404A1/en active Pending
- 2021-10-22 US US17/508,230 patent/US20220031824A1/en active Pending
- 2021-10-22 US US17/508,295 patent/US20220054613A1/en not_active Abandoned
- 2021-11-01 US US17/516,304 patent/US11576956B2/en active Active
- 2021-12-07 CY CY20211101070T patent/CY1124846T1/el unknown
- 2021-12-07 CY CY20211101071T patent/CY1124847T1/el unknown
- 2021-12-15 CY CY20211101104T patent/CY1124813T1/el unknown
-
2022
- 2022-04-25 US US17/728,756 patent/US11559573B2/en active Active
- 2022-06-29 US US17/853,334 patent/US11779638B2/en active Active
- 2022-06-29 US US17/853,344 patent/US11679147B2/en active Active
- 2022-06-29 US US17/852,623 patent/US11672848B2/en active Active
- 2022-11-09 AU AU2022268329A patent/AU2022268329A1/en active Pending
-
2023
- 2023-05-10 JP JP2023078113A patent/JP2023100927A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
JP2020182458A5 (hr) | ||
JP2020198875A5 (hr) | ||
JP2020191862A5 (hr) | ||
HRP20201228T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
HRP20201467T1 (hr) | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom | |
RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
JP2019513005A5 (hr) | ||
AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
JP2019516663A5 (hr) | ||
HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
JP2021101700A5 (hr) | ||
AR106920A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer | |
JP2019515650A5 (hr) | ||
HRP20230878T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raznih karcinoma (seq id 25 - mrax5-003) | |
JP2019520038A5 (hr) | ||
HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
JP2019536426A5 (hr) | ||
HRP20192212T4 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova | |
HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |